Actos Franchise Drives Takeda's Pharmaceutical Sales Growth
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm continues FDA discussions for new cholesterol candidate Tak-475.
You may also be interested in...
Takeda Cholesterol Drug Filing Set Back Due To Liver Enzyme Data
Takeda had planned to file TAK-475 in the first quarter of 2008 but is now awaiting additional study data.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.
Track-And-Trace: With Deadline a Year Away, Some Lessons from Early Adopters
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.